News

Title Content Date
Low levels of medication residues in the environment Researchers from the University of Stuttgart prove the degradation of diclofenac in soil samples for the first time 15.05.2018
Acousia Therapeutics Announces € 10 Million Series B Financing to Advance its Hearing Loss Portfolio TÜBINGEN, Germany, 14 May 2018 — Acousia Therapeutics (Acousia), a leader in the discovery and development of novel therapies in inner ear-related diseases and pathologies, today announced 14.05.2018
Immatics Appoints Stephen Eck as Chief Medical Officer US Immatics, a leading company in the field of cancer immunotherapy, today announced the appointment of Stephen Eck, M.D., Ph.D. as Chief Medical Officer (CMO) at Immatics US, Inc. 14.05.2018
CureVac Announces New Management Structure CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Founder and Chief Executive Officer, Dr. 08.05.2018
Curetis Publishes Full - Year 2017 Financial Results and Updated Guidance For 2018 Curetis N.V. 30.04.2018
Curetis Announces Change of the Composition of Its Supervisory Board Curetis N.V. (the "Company" and, together with Curetis GmbH and Curetis USA Inc., "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that Dr. 30.04.2018
Curetis to Raise EUR 4 .1 Million in Equity Offering with Access to Additional USD 10 million in Equity Over 36 Months Company to Issue 854,166 New Shares at EUR 4.80 Per Share 27.04.2018
Curetis to Publish its 2017 Annual Results on April 30, 2018 Curetis N.V., a developer of next-level molecular diagnostic solutions, today announced that it will publish its full-year 2017 financial results on April 30, 2018. 23.04.2018
Curetis Launches CE - IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018 Curetis N.V., a developer of next-level molecular diagnostic solutions, today announced the successful completion of clinical performance evaluation and CE-IVD marking of its novel Unyvero Applicat 19.04.2018
Curetis: Novel Products and Study Data to be Presented at ECCMID 2018 Curetis N.V., a developer of next-level molecular diagnostic solutions, today announced that the Company and its subsidiary Ares Genetics GmbH will present novel products, data, and service 18.04.2018

Pages